Further, in individuals diagnosed with both type 2 diabetes mellitus and either acute myeloid leukemia, chronic myeloid leukemia, or multiple myeloma, SGLT2 inhibitor use was associated with an increased risk of mortality. Here, SLC5A2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.